Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies
- 13 May 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (19), 1832-1839
- https://doi.org/10.1056/nejmsr0912039
Abstract
Prosecution and prevention of health care fraud and abuse are essential to reducing U.S. health care spending.1-3 A number of recent high-profile cases have uncovered suspect business practices and led to substantial recoveries; in September 2009, for example, Pfizer paid $2.3 billion to settle allegations that it marketed its drugs illegally to physicians, leading to unnecessary payments by the government.4Keywords
This publication has 10 references indexed in Scilit:
- Finding Money for Health Care Reform — Rooting Out Waste, Fraud, and AbuseNew England Journal of Medicine, 2009
- Shifting Terrain in the Regulation of Off-Label Promotion of PharmaceuticalsNew England Journal of Medicine, 2009
- Whistleblower-Initiated Enforcement Actions against Health Care Fraud and Abuse in the United States, 1996 to 2005Annals of Internal Medicine, 2008
- Defensive Medicine Among High-Risk Specialist Physicians in a Volatile Malpractice EnvironmentJAMA, 2005
- What Can We Learn from Medical Whistleblowers?PLoS Medicine, 2005
- Detecting Medicare abuseJournal of Health Economics, 2005
- A Qualitative Study of Increasing β-Blocker Use After Myocardial InfarctionJAMA, 2001
- A Systematic Approach for Using Qualitative Methods in Primary Prevention ResearchMedical Anthropology Quarterly, 1990
- Ten Whistleblowers and How They FaredThe Hastings Center Report, 1983